Subsequent Events (Details Narrative) - USD ($)	1 Months Ended			2 Months Ended
	Dec. 02, 2018	Nov. 28, 2018	Nov. 27, 2018	Dec. 21, 2018	Dec. 20, 2018	Dec. 01, 2018	Nov. 29, 2018	Nov. 25, 2018	Oct. 31, 2018	Oct. 26, 2018	Dec. 28, 2017	Jan. 18, 2017
Initial payment for Clinical Trial					$ 340,000
Aggregate Clinical Trial Cost									$ 2,118,461
Note amount								$ 1,060,000		$ 682,000
Purchase price of note								1,000,000		550,000
Investor fee										15,000
Original issue discount								$ 60,000		$ 122,000
Effective interest										27.50%	3.00%
LOI Terms		<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 28, 2018, Generex Biotechnology Corporation (the “Company”) and Regentys Corporation. (“Regentys”) entered into a binding letter of intent (“LOI”) contemplating the Company’s acquisition of 51% of the outstanding capital stock of Regentys for a total consideration of fifteen million dollars ($15,000,000) in accordance with the terms and conditions of the LOI (the "Proposed Acquisition").</p>	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 27, 2018, Generex Biotechnology Corporation (the “Company”) and Olaregen Therapeutix Inc. (“Olaregen”) entered into a binding letter of intent (“LOI”) contemplating the Company’s acquisition of 51% of the outstanding capital stock of Olaregen for a total consideration of twelve million dollars ($12,000,000) in accordance with the terms and conditions of the LOI (the "Proposed Acquisition").</p>
Exercise price												$ 2.50
Litigation awards for damages	$ 315,695
Litigation awards, exercisable shares	84,000
Exercise price	$ 2.50
Moscato
Common stock issued upon conversion							3,276,000
Salvo
Common stock issued upon conversion							3,354,645
B-H Sanford, LLC
Common stock issued upon conversion						25,200,000
Berkman
Shares exercisable						15,000,000
Exercise price						$ 2.50
Warrant terms				<p style="margin: 0"><font style="font-size: 10pt">The Warrant contains a provision prohibiting the exercise of the Warrant to the extent that, after exercise, Mr. Berkman would own more than 9.99% of the Company’s common stock. The Warrant was issued pursuant to the January 18, 2017 Acquisition Agreement among the Company, Hema Diagnostic Systems, LLC (“HDS”), Stephen L. Berkman and the other equity owners of HDS. Despite the warrants being issued after the effective date of the 20 for 1 stock dividend, per an agreement with warrant holder, such warrants were not subject to the stock dividend and no adjustment was made to the exercise price.</font></p>
Agreement terms				<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 1, 2018, the Company and Mr. Berkman entered into an Agreement, Assignment and Release, pursuant to which Mr. Berkman transferred the remaining HDS equity interests to the Company, waiving and releasing any conditions to such transfer. HDS is now a wholly owned subsidiary of the Company. The Company and Mr. Berkman released $624,404 owed to him by the Company and $13,431,706 owed to him by HDS, as of October 31, 2018, in exchange for shares of the Company’s common stock valued at the aggregate of such amount using the closing price for the common stock on November 30, 2018. The pre-stock dividend closing price was $18.99, resulting in 32,881 shares issuable to Mr. Berkman.</p>